(Q33620083)

28 July 2017

title

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial (English)

1 reference

28 July 2017

main subject

phase II clinical trial

0 references

author name string

C Bengala

1

1 reference

28 July 2017

F Bertolini

2

1 reference

28 July 2017

N Malavasi

3

1 reference

28 July 2017

C Boni

4

1 reference

28 July 2017

E Aitini

5

1 reference

28 July 2017

C Dealis

6

1 reference

28 July 2017

S Zironi

7

1 reference

28 July 2017

R Depenni

8

1 reference

28 July 2017

A Fontana

9

1 reference

28 July 2017

C Del Giovane

10

1 reference

28 July 2017

G Luppi

11

1 reference

28 July 2017

P Conte

12

1 reference

28 July 2017

language of work or name

English

0 references

publication date

24 November 2009

1 reference

British Journal of Cancer

28 July 2017

published in

1 reference

28 July 2017

volume

102

1 reference

28 July 2017

issue

1

1 reference

28 July 2017

page(s)

68-72

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605458

28 July 2017

exact match

0 references

cites work

Novel designs and end points for phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2813746

Phase II trial of sorafenib in metastatic thyroid cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2813746

Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2813746

Sorafenib in advanced hepatocellular carcinoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2813746

Design and endpoints of clinical trials in hepatocellular carcinoma.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2813746

Systemic therapy for biliary tract cancers

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2813746

Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2813746

Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2813746

Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2813746

Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2813746

Sorafenib in advanced clear-cell renal-cell carcinoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2813746

Biliary tract cancers: molecular profiling as a tool for treatment decisions. A literature review

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2813746

Raf: a strategic target for therapeutic development against cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2813746

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2813746

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2813746

Epidemiology and molecular pathology of gallbladder cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2813746

14 July 2018

Biliary tract cancers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2813746

Outcome of treatment for distal bile duct cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2813746

Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2813746

Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2813746

Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2813746

Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19935794

12 December 2020

inferred from PubMed ID database lookup

A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19935794

12 December 2020

inferred from PubMed ID database lookup

Validation of a new prognostic index for advanced epithelial ovarian cancer: results from its application to a UK-based cohort

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605458

7 January 2021

inferred from DOI database lookup

Gastrosplenic fistula from Hodgkin's lymphoma

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605458

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.BJC.6605458

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference